| scholarly article | Q13442814 |
| P50 | author | Kaj Blennow | Q28321550 |
| Henrik Zetterberg | Q6252048 | ||
| Ulf Andreasson | Q97016159 | ||
| Cynthia M Carlsson | Q114270827 | ||
| Mark A Sager | Q114336826 | ||
| Carey E. Gleason | Q117234552 | ||
| Hanna M. Blazel | Q117234582 | ||
| Sterling C. Johnson | Q51007286 | ||
| Michelle M Mielke | Q60909929 | ||
| Luigi Puglielli | Q92689767 | ||
| P2093 | author name string | Sanjay Asthana | |
| Norman J Haughey | |||
| Veera V R Bandaru | |||
| P2860 | cites work | Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics | Q21560953 |
| “Mini-mental state” | Q25938989 | ||
| Functional rafts in cell membranes | Q27860768 | ||
| Model systems, lipid rafts, and cell membranes | Q28261365 | ||
| Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 | ||
| Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers | Q29620245 | ||
| Deregulation of sphingolipid metabolism in Alzheimer's disease | Q33693061 | ||
| Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis | Q34007818 | ||
| Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss | Q34106300 | ||
| Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study | Q34274231 | ||
| Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. | Q34317415 | ||
| Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. | Q34588530 | ||
| Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease | Q35555867 | ||
| Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. | Q36149981 | ||
| Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway | Q36321788 | ||
| Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease | Q36604677 | ||
| Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease? | Q36768801 | ||
| Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling | Q37123974 | ||
| The liquid-ordered phase in membranes | Q37262381 | ||
| Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity | Q37291586 | ||
| Serum sphingomyelins and ceramides are early predictors of memory impairment | Q37437931 | ||
| Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. | Q40482351 | ||
| Neuropsychological prediction of decline to dementia in nondemented elderly | Q40784342 | ||
| Functions of ceramide in coordinating cellular responses to stress | Q41243489 | ||
| Depletion of plasma-membrane sphingomyelin rapidly alters the distribution of cholesterol between plasma membranes and intracellular cholesterol pools in cultured fibroblasts | Q41922039 | ||
| Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid | Q42474499 | ||
| Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention | Q42673976 | ||
| Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis | Q44370232 | ||
| Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia | Q44750872 | ||
| Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro | Q46663698 | ||
| Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin | Q46755710 | ||
| Alzheimer peptides perturb lipid-regulating enzymes | Q46873173 | ||
| Ceramide activates heterotrimeric protein phosphatase 2A. | Q48246807 | ||
| Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease | Q48557430 | ||
| Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity | Q49155965 | ||
| Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. | Q51576488 | ||
| Molecular recognition of a single sphingolipid species by a protein's transmembrane domain. | Q51762180 | ||
| Automatic detection vs controlled search: a paper-and-pencil approach. | Q52262016 | ||
| Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation. | Q53270598 | ||
| Sphingomyelin suppresses the binding and utilization of low density lipoproteins by skin fibroblasts | Q71160092 | ||
| Protein Phosphatase 2A Is the Major Enzyme in Brain that Dephosphorylates τ Protein Phosphorylated by Proline‐Directed Protein Kinases or Cyclic AMP‐Dependent Protein Kinase | Q71832645 | ||
| P433 | issue | 11 | |
| P921 | main subject | cerebrospinal fluid | Q54196 |
| Alzheimer's disease | Q11081 | ||
| sphingolipids | Q410395 | ||
| P304 | page(s) | 2486-2494 | |
| P577 | publication date | 2014-05-27 | |
| P1433 | published in | Neurobiology of Aging | Q7002141 |
| P1476 | title | Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease | |
| P478 | volume | 35 |
| Q47146081 | A Lipidomics Approach to Assess the Association Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature for Cognitive Response to Exercise. |
| Q47833026 | A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor |
| Q90231540 | Ceramide Accumulation Is Associated with Declining Verbal Memory in Coronary Artery Disease Patients: An Observational Study |
| Q101476188 | Ceramide analog [18F]F-HPA-12 detects sphingolipid disbalance in the brain of Alzheimer's disease transgenic mice by functioning as a metabolic probe |
| Q36409995 | Demographic and clinical variables affecting mid- to late-life trajectories of plasma ceramide and dihydroceramide species |
| Q46426783 | Differential regulation of sphingolipid metabolism in plasma, hippocampus, and cerebral cortex of mice administered sphingolipid modulating agents. |
| Q57476111 | Effects of Meditation and Music-Listening on Blood Biomarkers of Cellular Aging and Alzheimer's Disease in Adults with Subjective Cognitive Decline: An Exploratory Randomized Clinical Trial |
| Q26765300 | Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations |
| Q27026175 | Fingolimod for the treatment of neurological diseases-state of play and future perspectives |
| Q36481711 | Genome-wide DNA methylation profiling in the superior temporal gyrus reveals epigenetic signatures associated with Alzheimer's disease |
| Q26827532 | How does it STAC up? Revisiting the scaffolding theory of aging and cognition |
| Q47095000 | Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity |
| Q36361199 | Intracranial Arterial 4D-Flow is Associated with Metrics of Brain Health and Alzheimer's Disease |
| Q92423135 | Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers |
| Q58609636 | MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma |
| Q58751934 | Particular CSF sphingolipid patterns identify iNPH and AD patients |
| Q46248790 | Plasma sphingolipids and depressive symptoms in coronary artery disease |
| Q47840266 | Pleiotropic Effect of Human ApoE4 on Cerebral Ceramide and Saturated Fatty Acid Levels. |
| Q51761574 | Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease. |
| Q35566575 | Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's disease |
| Q36424510 | Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-β42, tau, and phospho-tau-181 levels |
| Q40401973 | The Association Between Plasma Ceramides and Sphingomyelins and Risk of Alzheimer's Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging. |
| Q38771128 | The role of ORMDL proteins, guardians of cellular sphingolipids, in asthma |
Search more.